Palabras clave
linfoma de Hodgkin pediátrico, linfoma de Hodgkin pediátrico recaído-refractario
Cómo citar
Veron, D. (2019). El linfoma de Hodgkin (LH) recaído-refractario (R/R) en pediatría y la necesidad de diseñar un tratamiento hecho a la medida de cada paciente. Revista Hematología, 22(1), 86–94. Recuperado a partir de https://www.revistahematologia.com.ar/index.php/Revista/article/view/116
Resumen
A pesar de los avances logrados en el tratamiento del linfoma de Hodgkin en pediatría sabemos que un porcentaje de pacientes se comportará como refractarios al tratamiento o recayendo en un tiempo variable. Sin embargo, en virtud de los cambios acontecidos en los últimos años en la terapia de primera línea y en las herramientas disponibles para el rescate de estos pacientes, este escenario merece discutirse y redefinirse.
Citas
1. Schellong et al. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOHHD study group. JCO. 2005 Sep 1;23(25):6181-9.
2. Shankar et al. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy. BJH. 2014 May;165(4):534-44.
3. Claviez A, Sureda A, Schmitz N. Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin's lymphoma. BMT. 2008 Oct;42 Suppl 2: S16-24.
4. Harker-Murray P et al. Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma. PBC. 2014 Apr;61(4):579-86.
5. Satwani et al. A Prognostic Model Predicting Autologous Transplantation Outcomes in Children, Adolescents and Young Adults with Hodgkin Lymphoma. BMT. 2015 Nov; 50(11):
1416-1423.
6. Gayoso J et al. Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin
Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. JCO. 2017 Oct 20;35(30):3425-3432.
7. Moskowitz et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 May 9;385(9980):1853-62.
8. Cole P, Schwartz CL, Drachtman R, de Alarcón P, Chen L, Trippett TM. Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin’s disease: a COG report. J Clin Oncol. 2009 Mar 20; 27(9): 1456-61.
9. Arai S, Letsinger R, Wong RM, Johnston LJ, Laport GG, Lowsky R, Miklos DB, Shizuru JA, Weng WK, Lavori PW, Blume KG, Negrin RS, Horning SJ. Phase I/II trial of GN-BVC,
a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory Hodgkin lymphoma. Biol Blood Marrow
Transplant. 2010 Aug;16(8):1145-54.
10. Cole P, McCarten K, Drachtman R, de Alarcon P, Chen L, Trippett T and Schwartz CL. Early FDG-PET-based Response Evaluation After Treatment with Gemcitabine and Vinorelbine
for Refractory Hodgkin Disease: A Children’s Oncology Group Report. Pediatr Hematol Oncol. 2010 November; 27(8): 650–657.
11. Santoro A, Magagnoli M, SpinaM, Pinotti G, Siracusano L, Michieli M, Nozza A, Sarina B, Morenghi E, Castagna L, Tirelli U, Balzarotti M. Ifosfamide, gemcitabine and vinorelbine: a
new induction regimen for refractory and relapsed Hodgkin's lymphoma. Hematologica. 2007 Jan;92(1):35-41.
12. Bonfante V, Viviani S, Santoro A, Devizzi L, Di Russo A, Zanini M, Soncini F, Soto Parra H, Valagussa P,Bonadonna G. Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease. Br J Haematol. 1998 Nov;103(2):533-5.
13. Locatelli et al. Phase 1/2 Study Of Brentuximab Vedotin In Pediatric Patients With Relapsed Or Refractory (R/R) Hodgkin Lymphoma (HL) Or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 Data For Brentuximab Vedotin 1.8 Mg/Kg In The HL Study Arm. Blood. 2013 122:4378.
14. Cheson et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016 128: 2489-2496.
15. Armstrong et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. JCO. 2009 May 10;27(14):2328-38.
16. Hanly et al. Measuring the societal burden of cancer: the cost of lost productivity due to premature cancer-related mortality in Europe. Int J Cancer. 2015 Feb 15;136(4): E136-45.
17. Hudson et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013 Jun 12;309(22):2371-2381.
2. Shankar et al. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy. BJH. 2014 May;165(4):534-44.
3. Claviez A, Sureda A, Schmitz N. Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin's lymphoma. BMT. 2008 Oct;42 Suppl 2: S16-24.
4. Harker-Murray P et al. Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma. PBC. 2014 Apr;61(4):579-86.
5. Satwani et al. A Prognostic Model Predicting Autologous Transplantation Outcomes in Children, Adolescents and Young Adults with Hodgkin Lymphoma. BMT. 2015 Nov; 50(11):
1416-1423.
6. Gayoso J et al. Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin
Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. JCO. 2017 Oct 20;35(30):3425-3432.
7. Moskowitz et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 May 9;385(9980):1853-62.
8. Cole P, Schwartz CL, Drachtman R, de Alarcón P, Chen L, Trippett TM. Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin’s disease: a COG report. J Clin Oncol. 2009 Mar 20; 27(9): 1456-61.
9. Arai S, Letsinger R, Wong RM, Johnston LJ, Laport GG, Lowsky R, Miklos DB, Shizuru JA, Weng WK, Lavori PW, Blume KG, Negrin RS, Horning SJ. Phase I/II trial of GN-BVC,
a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory Hodgkin lymphoma. Biol Blood Marrow
Transplant. 2010 Aug;16(8):1145-54.
10. Cole P, McCarten K, Drachtman R, de Alarcon P, Chen L, Trippett T and Schwartz CL. Early FDG-PET-based Response Evaluation After Treatment with Gemcitabine and Vinorelbine
for Refractory Hodgkin Disease: A Children’s Oncology Group Report. Pediatr Hematol Oncol. 2010 November; 27(8): 650–657.
11. Santoro A, Magagnoli M, SpinaM, Pinotti G, Siracusano L, Michieli M, Nozza A, Sarina B, Morenghi E, Castagna L, Tirelli U, Balzarotti M. Ifosfamide, gemcitabine and vinorelbine: a
new induction regimen for refractory and relapsed Hodgkin's lymphoma. Hematologica. 2007 Jan;92(1):35-41.
12. Bonfante V, Viviani S, Santoro A, Devizzi L, Di Russo A, Zanini M, Soncini F, Soto Parra H, Valagussa P,Bonadonna G. Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease. Br J Haematol. 1998 Nov;103(2):533-5.
13. Locatelli et al. Phase 1/2 Study Of Brentuximab Vedotin In Pediatric Patients With Relapsed Or Refractory (R/R) Hodgkin Lymphoma (HL) Or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 Data For Brentuximab Vedotin 1.8 Mg/Kg In The HL Study Arm. Blood. 2013 122:4378.
14. Cheson et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016 128: 2489-2496.
15. Armstrong et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. JCO. 2009 May 10;27(14):2328-38.
16. Hanly et al. Measuring the societal burden of cancer: the cost of lost productivity due to premature cancer-related mortality in Europe. Int J Cancer. 2015 Feb 15;136(4): E136-45.
17. Hudson et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013 Jun 12;309(22):2371-2381.
Todo el material publicado en la revista Hematología (versión electrónica y versión impresa), será cedido a la Sociedad Argentina de Hematología. De conformidad con la ley de derecho de autor (ley 11723) se les enviara a los autores de cada trabajo aceptado formulario de cesión de derechos de autor que deberá ser firmado por todos los autores antes de la publicación. Los autores deberán retener una copia del original pues la revista, no acepta responsabilidad por daños o pérdidas del material enviado. Los autores deberán remitir una versión electrónica al correo: revista@sah.org.ar
Descargas
Los datos de descargas todavía no están disponibles.